

Corrigendum to: Transcriptome Assessment of Erythema Migrans Skin Lesions in Patients With Early Lyme Disease Reveals Predominant Interferon Signaling

Adriana Marques,¹ Ira Schwartz,² Gary P Wormser,³ Yanmei Wang,⁴ Ronald L Hornung,⁴ Cumhuri Y Demirkale,⁵ Peter J Munson,⁵ Siu-Ping Turk,¹ Carla Williams,⁴ Chyi-Chia Richard Lee,⁶ Jun Yang,⁷ and Mary M Petzke²

¹Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland; ²Department of Microbiology and Immunology and ³Division of Infectious Diseases, Department of Medicine, New York Medical College, Valhalla; ⁴Clinical Services Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Maryland; ⁵Mathematical and Statistical Computing Laboratory, Center for Information Technology, National Institutes of Health, Bethesda, Maryland; ⁶Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; ⁷Laboratory of Human Retrovirology and Immunoinformatics, Leidos Biomedical Research, Inc. Frederick National Laboratory for Cancer Research, Maryland

In “Transcriptome Assessment of Erythema Migrans Skin Lesions in Patients With Early Lyme Disease Reveals Predominant Interferon Signaling” by Marques et al. [*J*

Infect Dis, doi:10.1093/infdis/jix563], the authors wish to make readers aware that their dataset is publicly available at GSE154916.

DOI: 10.1093/infdis/jiaa499

Corrigendum to: Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial

Carl J. Fichtenbaum,¹ Heather J. Ribaldo,² Jorge Leon-Cruz,² Edgar T. Overton,³ Markella V. Zanni,⁴ Carlos D. Malvestutto,⁵ Judith A. Aberg,⁶ Emma M. Kileel,⁴ Kathleen V. Fitch,⁴ Marije Van Schalkwyk,⁷ Nagalingeswaran Kumarasamy,⁸ Esteban Martinez,⁹ Breno Riegel Santos,¹⁰ Yvetot Joseph,¹¹ Janet Lo,⁴ Sue Siminski,¹² Kathleen Melbourne,¹³ Craig A. Sponseller,¹⁴ Patrice Desvigne-Nickens,¹⁵ Gerald S. Bloomfield,¹⁶ Judith S. Currier,¹⁷ Udo Hoffmann,¹⁸ Pamela S. Douglas,¹⁹ and Steven K. Grinspoon⁴, on behalf of the REPRIEVE Investigators³

¹Division of Infectious Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA, ²Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA, ³Division of Infectious Diseases, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA, ⁴Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA, ⁵Division of Infectious Diseases, Ohio State University Medical Center, Columbus, Ohio, USA, ⁶Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA, ⁷Family Centre for Research with Ubuntu, Division of Adult Infectious Diseases, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa, ⁸Infectious Diseases Medical Centre, Voluntary Health Services, Chennai, India, ⁹Hospital Clinic and University of Barcelona, Barcelona, Spain, ¹⁰Infectious Diseases Service, Hospital Nossa, Senhora da Conceição/GHC, Porto Alegre, Brazil, ¹¹Les Centres GHESKIO, Port-au-Prince, Haiti, ¹²Frontier Science and Technology Foundation, Amherst, Massachusetts, USA, ¹³HIV Medical Sciences, Gilead Sciences, Foster City, California, USA, ¹⁴Kowa Pharmaceuticals America, Montgomery, Alabama, USA, ¹⁵National Heart, Lung and Blood Institute, Baltimore, Maryland, USA, ¹⁶Department of Medicine, Duke Global Health Institute and Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA, ¹⁷Division of Infectious Diseases, University of California-Los Angeles, Los Angeles, California, USA, ¹⁸Cardiac MR PET CT Program and Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA, and ¹⁹Duke University Medical Center, Durham, North Carolina, USA

In “Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial” by Fichtenbaum et al. [*J Infect Dis*, 2020;222(S1):S8–19, doi:10.1093/infdis/jiaa259], the list of contributors were

provided as supplementary material. This has now been moved to the acknowledgment section of the article. The online version of this article has been corrected to reflect this change.

DOI: 10.1093/infdis/jiaa594